Literature DB >> 10971312

Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations.

J M Morsman1, J Sludden, M M Ameyaw, J Githang'A, A Indalo, D Ofori-Adjei, H L McLeod.   

Abstract

AIMS: Dihydropyrimidine dehydrogenase (DPD) reduces endogenous pyrimidines and therapeutic analogues such as the anticancer agent 5-fluorouracil (5FU). Among Caucasian populations DPD activity is highly variable and subject to polymorphic regulation. To evaluate interethnic influence, DPD activity was assessed in South-west Asian, Kenyan and Ghanaian populations.
METHODS: DPD activity was determined in peripheral mononuclear cells using[14C]-5-fluorouracil and h.p.l.c. analysis.
RESULTS: A high degree of variation in DPD activity was observed within each population (range CV = 34-48%). Median DPD activity also varied between these populations. South-west Asian and Kenyan subjects exhibited almost identical median values (192 and 193.5 pmol min(-1) mg(-1), respectively), which were similar to Caucasians (median 215 pmol min(-1) mg(-1). A significantly lower median DPD activity (119 pmol min(-1) mg(-1)) was observed in the Ghanaian population.
CONCLUSIONS: The similarity in DPD activity between Caucasian, Kenyan and South-west Asian populations suggests that the incidence of 5FU-related toxicity may be comparable in these groups. The pharmacokinetic implications of lower activity amongst Ghanaians needs to be evaluated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971312      PMCID: PMC2014976          DOI: 10.1046/j.1365-2125.2000.00242.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations.

Authors:  E S Collie-Duguid; S C Pritchard; R H Powrie; J Sludden; D A Collier; T Li; H L McLeod
Journal:  Pharmacogenetics       Date:  1999-02

2.  Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals.

Authors:  H L McLeod; S C Pritchard; J Githang'a; A Indalo; M M Ameyaw; R H Powrie; L Booth; E S Collie-Duguid
Journal:  Pharmacogenetics       Date:  1999-12

3.  Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome.

Authors:  B E Harris; J T Carpenter; R B Diasio
Journal:  Cancer       Date:  1991-08-01       Impact factor: 6.860

4.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

5.  Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.

Authors:  R A Fleming; G Milano; A Thyss; M C Etienne; N Renée; M Schneider; F Demard
Journal:  Cancer Res       Date:  1992-05-15       Impact factor: 12.701

6.  Dihydropyrimidine dehydrogenase activity in a Korean population.

Authors:  D R Sohn; M S Cho; P J Chung
Journal:  Ther Drug Monit       Date:  1999-04       Impact factor: 3.681

7.  Effect of vitamin B2 deficiency on rat liver dihydropyrimidine dehydrogenase activity.

Authors:  S Fujimoto; K Matsuda; M Kikugawa; M Kaneko; N Tamaki
Journal:  J Nutr Sci Vitaminol (Tokyo)       Date:  1991-02       Impact factor: 2.000

8.  Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.

Authors:  Z Lu; R Zhang; R B Diasio
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

9.  Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.

Authors:  C H Takimoto; Z H Lu; R Zhang; M D Liang; L V Larson; L R Cantilena; J L Grem; C J Allegra; R B Diasio; E Chu
Journal:  Clin Cancer Res       Date:  1996-03       Impact factor: 12.531

10.  Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver.

Authors:  M Chazal; M C Etienne; N Renée; A Bourgeon; H Richelme; G Milano
Journal:  Clin Cancer Res       Date:  1996-03       Impact factor: 12.531

View more
  7 in total

1.  A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.

Authors:  M Wasif Saif; Adam M Lee; Steven M Offer; Kathleen McConnell; Valerie Relias; Robert B Diasio
Journal:  Mayo Clin Proc       Date:  2014-01       Impact factor: 7.616

Review 2.  Clinically relevant genetic variations in drug metabolizing enzymes.

Authors:  Navin Pinto; M Eileen Dolan
Journal:  Curr Drug Metab       Date:  2011-06       Impact factor: 3.731

3.  Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.

Authors:  Samar Ismail Hamdy; Masahiro Hiratsuka; Kaori Narahara; Mervat El-Enany; Nadia Moursi; Mohammed Salah-Eldin Ahmed; Michinao Mizugaki
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

4.  Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?

Authors:  Vijay M Patil; Vanita Noronha; Amit Joshi; Saurabh Zanwar; Anant Ramaswamy; Supreeta Arya; Abhishek Mahajan; Atanu Bhattacharjee; Kumar Prabhash
Journal:  South Asian J Cancer       Date:  2016 Oct-Dec

Review 5.  Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase.

Authors:  Filippo Merloni; Nicoletta Ranallo; Laura Scortichini; Riccardo Giampieri; Rossana Berardi
Journal:  Cancer Drug Resist       Date:  2019-09-19

Review 6.  Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature.

Authors:  Cassandra White; Rodney J Scott; Christine Paul; Andrew Ziolkowski; David Mossman; Stephen Ackland
Journal:  Pharmgenomics Pers Med       Date:  2021-12-09

7.  A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity.

Authors:  S M Offer; A M Lee; L K Mattison; C Fossum; N J Wegner; R B Diasio
Journal:  Clin Pharmacol Ther       Date:  2013-04-03       Impact factor: 6.875

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.